{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011626","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.438210+00:00","generated_at":"2026-05-31T11:06:05.220180+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024","bullets":["Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.","Cash, cash equivalents and restricted cash fell to $77.4M from $117.5M as of Dec 31, 2023.","Malte Peters appointed CEO and Terry Coelho as EVP & CFO effective July 22, 2024.","Eseba-vec (HB-200) AVALON-1 Phase 2/3 trial aligned with FDA; start expected Q4 2024.","Received $5M milestone from Gilead for HB-500 HIV Phase 1b first dosing; $10M from Roche for HB-700 IND."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011626","json":"https://secwatch.observer/filing/0001558370-24-011626.json","markdown":"https://secwatch.observer/filing/0001558370-24-011626.md","text":"https://secwatch.observer/filing/0001558370-24-011626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024011626/0001558370-24-011626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024011626/hook-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:06:05.220180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}